

16th ANNUAL



STATE OF THE HEART SYMPOSIUM – 2025

VIRTUAL

Conference Learning Objectives

- Analyze the latest advancements in cardiovascular and metabolic disease
- Interpret and apply current cardiovascular guidelines
- Evaluate clinical trial results and their impact on patient care

Conference Date & Time

SESSION 1 Wednesday, June 4th
(7:10 - 9:15 pm EDT)

SESSION 2 Wednesday, June 11th
(7:10- 9:15 pm EDT)

SESSION 3 Wednesday, June 18th
(7:10- 9:15 pm EDT)

Conference Co-Chairs



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)
 Assistant Professor,
 Department of Medicine,
 University of Toronto
 Medical Director,
 Collaborative CME & Research Network
 Brampton, ON



Megha Poddar

MD, FRCPC, ABOM
 Clinical Director, LMC Weight
 Management Centre
 Assistant Clinical Professor
 (Adjunct), McMaster University
 Toronto, ON

CFPC Accreditation

This activity has been certified by the College of Family Physicians of Canada for up to 6.0 Mainpro+® Certified Activity credits.

Certified Program Agenda

Faculty

SESSION 1: Wednesday, June 4th (7:10 - 9:15 pm EDT)

7:10 PM	Welcome and Introductions	Milan Gupta
7:20 PM	Wearable technology in healthcare: Friend or foe?	Arun Sridhar
7:40 PM	Diabetes update: What's new in the 2024 guidelines?	Sonia Butalia
8:00 PM	The patient with CKD: Which drugs and when?	Rita Suri
8:20 PM	Common pitfalls in anticoagulation for atrial fibrillation	Jason Andrade
8:40 PM	Q&A	
9:10 PM	Closing Comments	

SESSION 2: Wednesday, June 11th (7:10 - 9:15 pm EDT)

7:10 PM	Welcome and Introductions	Milan Gupta
7:20 PM	Applying lipid guidelines in primary prevention	Liam Brunham
7:40 PM	Lipid management of the post-MI patient	Milan Gupta
8:00 PM	The patient with elevated Lp(a): What to do?	Iulia Iatan
8:20 PM	What's in the pipeline in lipid management?	Deepak Bhatt
8:40 PM	Q&A	
9:10 PM	Closing Comments	

SESSION 3: Wednesday, June 18th (7:10 - 9:15 pm EDT)



7:10 PM	Welcome and Introductions	Milan Gupta
7:20 PM	How to diagnose and treat HFpEF in primary care	Stephanie Poon
7:40 PM	Challenges in treating HFrEF in primary care	Peter Liu
8:00 PM	GLP-1-based treatments for cardiovascular disease	Kim Connelly
8:20 PM	What's in the pipeline for obesity management?	Megha Poddar
8:40 PM	Q&A	
9:10 PM	Closing Comments	



Register Now →

Visit at: www.ccrnmd.com

This program has received unrestricted educational funding support from:

 **Gold:** Amgen, Ultragenyx, AstraZeneca
 **Silver:** Eli Lilly, Merck, Boehringer Ingelheim

For inquiries regarding this program,
 please contact info@ccrnmd.com




Program Agenda

Time	Topic	Learning Objective	Faculty
SESSION 1: Wednesday, June 4th (7:10 - 9:15 pm EDT)			
7:10 - 7:20 PM	Welcome and Introductions		Milan Gupta
7:20 - 7:40 PM	Wearable technology in healthcare: Friend or foe?	Evaluate the benefits and challenges of wearable technology in cardiovascular healthcare	Arun Sridhar
7:40 - 8:00 PM	Diabetes update: What's new in the 2024 guidelines?	Analyze the key updates in the 2024 diabetes guidelines and their implications for cardiovascular risk management and patient care.	Sonia Butalia
8:00 - 8:20 PM	The patient with CKD: Which drugs and when	Evaluate the role of SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone in the management of patients with chronic kidney disease (CKD) and cardiovascular risk.	Rita Suri
8:20 - 8:40 PM	Common pitfalls in anticoagulation for atrial fibrillation	Implement evidence-based strategies to optimize patient safety, adherence, and therapeutic outcomes for patients with atrial fibrillation	Jason Andrade
8:40 - 9:10 PM	Q&A		
9:10 - 9:15 PM	Closing Comments		
SESSION 2: Wednesday, June 11th (7:10 - 9:15 pm EDT)			
7:10 - 7:20 PM	Welcome and Introductions		Milan Gupta
7:20 - 7:40 PM	Applying lipid guidelines in primary prevention	Implement current lipid guidelines in primary prevention by assessing cardiovascular risk and optimizing lipid-lowering therapy for at-risk patients.	Liam Brunham
7:40 - 8:00 PM	Lipid management of the post-MI patient	Optimize lipid management and reduce recurrent cardiovascular events for post-MI patients.	Milan Gupta
8:00 - 8:20 PM	The patient with elevated Lp(a): What to do?	Develop evidence-based strategies for assessing and managing patients with elevated lipoprotein(a) [Lp(a)] to reduce cardiovascular risk.	Iulia Iatan


[Register Now →](#)

 Visit at: www.ccrnmd.com

This program has received unrestricted educational funding support from:


Gold: Amgen, Ultragenyx, AstraZeneca
Silver: Eli Lilly, Merck, Boehringer Ingelheim

 For inquiries regarding this program, please contact info@ccrnmd.com



Program Agenda



Time	Topic	Learning Objective	Faculty
SESSION 2: Wednesday, June 11th (7:10 - 9:15 pm EDT)			
8:20 - 8:40 PM	What's in the pipeline in lipid management?	Explore emerging therapies and advancements in lipid management and their potential impact on cardiovascular risk reduction.	Deepak Bhatt
8:40 - 9:10 PM	Q&A		
9:10 - 9:15 PM	Closing Comments		
SESSION 3: Wednesday, June 18th (7:10 - 9:15 pm EDT)			
7:10 - 7:20 PM	Welcome and Introductions		Milan Gupta
7:20 - 7:40 PM	How to diagnose and treat HFpEF in primary care	Identify key clinical, diagnostic, and imaging criteria to accurately diagnose heart failure with preserved ejection fraction (HFpEF) in primary care.	Stephanie Poon
7:40 - 8:00 PM	Challenges in treating HFrEF in primary care	Implement effective strategies to optimize HFrEF management by primary care physicians	Peter Liu
8:00 - 8:20 PM	GLP-1-based treatments for cardiovascular disease	Implement effective risk reduction strategies for patients with obesity and cardiovascular disease to improve outcomes.	Kim Connelly
8:20 - 8:40 PM	What's in the pipeline for obesity management?	Examine emerging therapies and innovative approaches in obesity management and their potential impact on cardiovascular risk reduction.	Megha Poddar
8:40 - 9:10 PM	Q&A		
9:10 - 9:15 PM	Closing Comments		



Register Now →

Visit at: www.ccrnmd.com

This program has received unrestricted educational funding support from:

 **Gold:** Amgen, Ultragenyx, AstraZeneca
 **Silver:** Eli Lilly, Merck, Boehringer Ingelheim

For inquiries regarding this program, please contact info@ccrnmd.com



Program Agenda

Conference Learning Objectives

- Analyze the latest advancements in cardiovascular and metabolic disease
- Interpret and apply current cardiovascular guidelines
- Evaluate clinical trial results and their impact on patient care

Non-Certified Conference Date & Time

SESSION 1 **Wednesday, June 4th**
(6:45 - 9:15 pm EDT)

SESSION 2 **Wednesday, June 11th**
(6:45 - 9:15 pm EDT)

SESSION 3 **Wednesday, June 18th**
(6:45 - 9:15 pm EDT)

Conference Co-Chairs



Milan Gupta
 MD, FRCPC, FCCS, CPC(HC)
 Assistant Professor, Department of Medicine,
 University of Toronto
 Medical Director,
 Collaborative CME and Research Network
 Brampton, ON



Megha Poddar
 MD, FRCPC, ABOM
 Clinical Director, LMC Weight Management Centre
 Assistant Clinical Professor
 (Adjunct), McMaster University

Non-Certified Program Agenda

Faculty

SESSION 1: Wednesday, June 4th (6:45 - 7:10 pm EDT)

Lipid guidelines: finding common ground

Robert Hegele

Learning Objectives

- Review current CCS and PEER lipid guidelines
- Identify similarities and reconcile disagreements between them
- Suggest a pragmatic path forward

This session is not certified by the College of Family Physicians of Canada.

SESSION 2: Wednesday, June 11th (6:45 - 7:10 pm EDT)

FH : It's A Family Affair

Clinical Clues and Genetic Keys to Early Targeted Treatment for Familial Hypercholesterolemia

Robert Hegele

Learning Objectives

- Understand genetic and clinical methods to differentiate HeFH and HoFH.
- Explore diagnostic approaches through case studies.
- Review current treatment options for FH.

This session is not certified by the College of Family Physicians of Canada.

SESSION 3: Wednesday, June 18th (6:45 - 7:10 pm EDT)

ATTR Amyloidosis: A Modern Approach to Diagnosis & Care



Margot Davis

Learning Objectives:

- Recognize the spectrum of symptoms and clinical presentations associated with ATTR.
- Understand the diagnostic tools to identify ATTR early and differentiate it from similar conditions.
- Learn when to refer and the importance of a multidisciplinary approach for effective patient management and coordination of care.

This session is not certified by the College of Family Physicians of Canada.

This program has received unrestricted educational funding support from:

 **Gold:** Amgen, Ultragenyx, AstraZeneca
 **Silver:** Eli Lilly, Merck, Boehringer Ingelheim



Register Now →

Visit at: www.ccrnmd.com

For inquiries regarding this program,
 please contact info@ccrnmd.com